Celecoxib is associated with fewer small bowel lesions than naproxen+omeprazole in healthy subjects as determined by capsule endoscopy

Goldstein, Jay L; Eisen, Glenn; Lewis, Blair; Gralnek, Ian; Fort, John G; Zlotnick, Steve
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS297
Academic Journal
An abstract of the article "Celecoxib is associated with fewer small bowel lesions than naproxen+omeprazole in healthy subjects as determined by capsule endoscopy," by Jay L Goldstein and colleagues is presented.


Related Articles

  • No Safety Edge for Celebrex, Says FDA Panel.  // Nutrition Health Review: The Consumer's Medical Journal;2001, Issue 81, p15 

    Focuses on the advantages of the arthritis drug celecoxib. Absence of causing stomach-related problems; Protection of the stomach lining; Comparison of the drug with the traditional pain killers.

  • Correction.  // Clinical Pharmacology & Therapeutics;Dec2006, Vol. 80 Issue 6, p702 

    A correction to the article "Modulation of celecoxib pharmacokinetics by Food in Pediatric Patients" that was published in the previous issue is presented.

  • Correction.  // Advertising Age;9/13/2004, Vol. 75 Issue 37, p22 

    Presents a correction to the article "Celebrex Effort Will Not Exploit Vioxx Study," that was previously published in the September 6, 2004 issue of "Advertising Age."

  • Multiple drugs.  // Reactions Weekly;9/25/2010, Issue 1320, p35 

    The article describes the case of a 40-year-old woman who developed a maculopapular and urticarial erythematous rash, hypoglycemia, osteoporosis, erythema nodosum and injection site pain while receiving clecoxib, ciclosporin, prednisolone, infliximab and anakinra for adult-onset Still's disease.

  • Celecoxib.  // Reactions Weekly;10/20/2012, Issue 1424, p19 

    The article describes the case of a 62-year-old woman who developed anaphylaxis after receiving celecoxib for arthralgia.

  • 2008 - Review: Celecoxib increases risk for cardiovascular events; risks are greatest with higher doses. Rothschild, Bruce // ACP Journal Club;9/16/2008, Vol. 149 Issue 3, p13 

    The article provides an answer to the question if long-term use of celecoxib increase risk for cardiovascular events and if the risk is dose-dependent.

  • ATC/DDD Classification (temporary).  // WHO Drug Information;2003, Vol. 17 Issue 3, p181 

    Presents the temporary anatomical therapeutic chemical classifications and defined daily doses which were agreed at a meeting of the World Health Organization International Working Group for Drug Statistics Methodology on May 26-27, 2003. Celecoxib; Atomoxetine; Bemiparin; Levosulpiride; Trospium.

  • COX-2 Inhibitors vs. NSAIDs in Treatment of Arthritis. Walling, Anne D. // American Family Physician;1/15/2003, Vol. 67 Issue 2, p406 

    Discusses the study 'Efficacy, Tolerability, and Upper Gastrointestinal Safety of Celecoxib for Treatment of Osteoarthritis and Rheumatoid Arthritis: Systematic Review of Randomised Controlled Trials,' by J.J. Deeks et al., from the September 21, 2002 issue of the 'British Medical Journal.'

  • Coxibs and cardiovascular risk. Pijak, Michal R.; Huzicka, Igor; Gazdik, Frantisek // CMAJ: Canadian Medical Association Journal;10/11/2005, Vol. 173 Issue 8, p852 

    Presents a letter to the editor in response to the article "New Restrictions on Celecoxib (Celebrex) Use and the Withdrawal of Valdecoxib (Bextra)," by Jill Cotter and Eric Wooltorton in the 2005 issue of the "Canadian Medical Association Journal."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics